Type: rating_growth

Analysts Jefferies upgraded Chemed (CHE) to Buy and raised target price to $620, expecting 22% upside

Jefferies has upgraded Chemed to a 'buy' rating and increased its price target to $620, indicating a potential 22% upside, following the company's strong third-quarter earnings that exceeded expectations. This upgrade reflects confidence in Chemed's recovery from recent operational challenges and its ability to regain a premium valuation.

Analysts Morgan Stanley upgraded Lockheed Martin (LMT) to overweight and raised target price to $835, citing strong future prospects

Several companies experienced significant stock movements, with Lockheed Martin and CACI International gaining on analyst upgrades, while JetBlue Airways faced a sharp decline amid restructuring concerns. These developments highlight the volatility and potential opportunities in the defense and airline sectors.